MetaVia Inc., a clinical-stage biotechnology company, has announced the dosing of the first patient in the 48 mg multiple ascending dose cohort of its Phase 1 clinical trial for DA-1726, a dual oxyntomodulin analog agonist designed for obesity treatment. This trial aims to explore the maximum tolerated dose of DA-1726, which functions as both a glucagon-like peptide-1 receptor and glucagon receptor agonist. Previous data from the 32 mg dose has indicated potential therapeutic benefits, such as dose-dependent weight loss and waist reduction, without inducing hypoglycemia. The drug has also demonstrated favorable cardiovascular safety and tolerability profiles. MetaVia expects to present the top-line data from the 48 mg cohort in the fourth quarter of 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。